CTLA4 and metastatic neoplasm: The prognosis for both locally advanced and metastatic tumours is significantly improved by inhibiting immunological checkpoints that suppress antitumoral immune responses, such as programmed cell death (PD-1), its ligand PD-L1, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).